



Tuesday 13 December 2011

Australian Securities Exchange Announcement

STANFORD UNIVERSITY INITIATES BREAST CANCER LYMPHOEDEMA REGISTRY

Brisbane, Australia – Stanford University Medical Center announced today the initiation of a breast cancer lymphoedema registry that will collect and analyse data from breast centres across the United States. ImpediMed Limited (ASX: IPD) (“ImpediMed” or “the Company”) is providing financial support for the project through an unrestricted educational grant to the University and the registry’s principal investigator and lymphoedema expert, Dr. Stanley Rockson.

A medical registry collects clearly defined health and demographic information on patients with specific health characteristics, in this case, breast cancer. The data is held in a central database. That data is then mined by the investigators in order to gain insight into the natural history and optimal treatment of the condition. The Stanford Breast Cancer Lymphedema Registry has been designed to investigate the impact of lymphoedema surveillance upon breast cancer survivors. One arm of the registry will collect information on patients being monitored using the Company’s bioimpedance spectroscopy device, the L-Dex® U400. The registry is governed by a Stanford University Institutional Review Board and will be listed on clinicaltrials.gov as soon as it begins enrollment.

“This registry represents a major step forward for breast cancer therapeutics and breast cancer survivorship. Within a year, we expect to have gained further substantial insights into the value of systematic early surveillance to prevent and minimize the lymphoedema risk in women treated for breast cancer”, said the Registry’s principal investigator, Dr. Stanley Rockson. Dr. Rockson is recognized as a global expert in lymphoedema and holds an endowed chair in lymphatic research and medicine at Stanford University School of Medicine. Dr. Rockson is also Director of Stanford’s Center for Lymphatic and Venous Disorders.

Greg Brown, CEO commented, “The registry represents another key milestone achieved by the Company. Within the world of lymphoedema, Dr. Rockson is recognized as an expert clinician, a gifted researcher and a prolific writer and editor. The Registry will collect patient data from both BIS and non-BIS users. Physicians and surgeons, from across the U.S., will help facilitate patient awareness of the Registry in order to encourage enrollment. ImpediMed is pleased to support such vital research through such a well respected academic centre as Stanford.

The following link is to the Stanford announcement on the registry. The significance of this announcement for shareholders is for understanding the role of the registry in supporting the continued clinical validation of pre-emptive care in the prospective management of female breast cancer patients.

<http://med.stanford.edu/ism/2011/december/lymphedema.html>

Greg Brown
CEO

ENDS

For further information contact:

Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

L-Dex[®] is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm in women by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit: www.impedimed.com.